Home・Список акций・BioNTech SE ADR

BioNTech SE ADR

Закрыт

СекторЗдравоохранение

89.05 -3.32

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

88.89

Макс.

92.09

Ключевые показатели
By Trading Economics
Доход	-239M -541M
Продажи	-779M 120M
Прибыль на акцию	-1.95
Рентабельность продаж	-450.381
Сотрудники	7,807
EBITDA	-383M -450M

Рекомендации
By TipRanks
Рекомендации	Активная покупка
Прогноз на 12 месяцев	+40.88% upside

Дивиденды
By Acuity
Следующий отчет о доходах	4 авг. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	-1.8B 23B
Предыдущая цена открытия	92.37
Предыдущая цена закрытия	89.05

Новостные настроения

By Acuity

100%

324 / 340 Рейтинг в Healthcare

BioNTech SE ADR График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

24 июл. 2026 г., 19:06 UTC

BioNTech SE shares are lower today, continuing a decline amid broader market pressure and a significant drop in crude oil prices.

22 июл. 2026 г., 18:06 UTC

BioNTech SE shares are lower today, reflecting broader market caution amid rising crude oil prices and geopolitical tensions ahead of major technology earnings reports.

21 июл. 2026 г., 14:41 UTC

News

BioNTech SE is rising amid positive market sentiment and plans to report second-quarter 2026 results on August 4, 2026. The Nasdaq 100 Index is also up.

20 июл. 2026 г., 19:06 UTC

News

BioNTech SE shares are higher today, supported by a positive analyst outlook and an average recommendation of "Moderate Buy" from nineteen brokerage firms.

Сравнение c конкурентами

Изменение цены

BioNTech SE ADR Прогноз

Целевая цена

By TipRanks

40.88% рост

Прогноз на 12 месяцев

Средняя 125.85 USD 40.88%

Максимум 158 USD

Минимум 94 USD

Основано на мнении 13 аналитиков Wall Street, спрогнозировавших целевые цены для BioNTech SE ADR на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

13 ratings

Покупка

Удержание

Продажа

Основано на мнении 13 аналитиков, присваивавших рейтинги акциям BioNTech SE ADR – Данные за последние 3 месяца.

Настроения

By Acuity

324 / 340Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании BioNTech SE ADR

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac